164 related articles for article (PubMed ID: 33159495)
21. In silico, in vitro and case-control analyses as an effective combination for analyzing BRCA1 and BRCA2 unclassified variants in a population-based sample.
Rodríguez-Balada M; Roig B; Martorell L; Melé M; Salvat M; Vilella E; Borràs J; Gumà J
Cancer Genet; 2016 Nov; 209(11):487-492. PubMed ID: 27886673
[TBL] [Abstract][Full Text] [Related]
22. Investigating the effect of 28 BRCA1 and BRCA2 mutations on their related transcribed mRNA.
Quiles F; Menéndez M; Tornero E; del Valle J; Teulé À; Palanca S; Izquierdo A; Gómez C; Campos O; Santamaria R; Brunet J; Capellá G; Feliubadaló L; Lázaro C
Breast Cancer Res Treat; 2016 Jan; 155(2):253-60. PubMed ID: 26780556
[TBL] [Abstract][Full Text] [Related]
23. Identification and Characterization of a New BRCA2 Rearrangement in an Italian Family with Hereditary Breast and Ovarian Cancer Syndrome.
Concolino P; Rizza R; Hackmann K; Minucci A; Scaglione GL; De Bonis M; Costella A; Zuppi C; Schrock E; Capoluongo E
Mol Diagn Ther; 2017 Oct; 21(5):539-545. PubMed ID: 28620890
[TBL] [Abstract][Full Text] [Related]
24. RNA analysis of eight BRCA1 and BRCA2 unclassified variants identified in breast/ovarian cancer families from Spain.
Campos B; Díez O; Domènech M; Baena M; Balmaña J; Sanz J; Ramírez A; Alonso C; Baiget M
Hum Mutat; 2003 Oct; 22(4):337. PubMed ID: 12955719
[TBL] [Abstract][Full Text] [Related]
25. From a variant of unknown significance to pathogenic: Reclassification of a large novel duplication in BRCA2 by high-throughput sequencing.
van Luttikhuizen JL; Bublitz J; Schubert S; Schmidt G; Hofmann W; Morlot S; Buurman R; Auber B; Schlegelberger B; Steinemann D
Mol Genet Genomic Med; 2020 Sep; 8(9):e1045. PubMed ID: 31724318
[TBL] [Abstract][Full Text] [Related]
26. Germline EMSY sequence alterations in hereditary breast cancer and ovarian cancer families.
Määttä KM; Nurminen R; Kankuri-Tammilehto M; Kallioniemi A; Laasanen SL; Schleutker J
BMC Cancer; 2017 Jul; 17(1):496. PubMed ID: 28738860
[TBL] [Abstract][Full Text] [Related]
27. A high proportion of DNA variants of BRCA1 and BRCA2 is associated with aberrant splicing in breast/ovarian cancer patients.
Sanz DJ; Acedo A; Infante M; Durán M; Pérez-Cabornero L; Esteban-Cardeñosa E; Lastra E; Pagani F; Miner C; Velasco EA
Clin Cancer Res; 2010 Mar; 16(6):1957-67. PubMed ID: 20215541
[TBL] [Abstract][Full Text] [Related]
28. Thorough in silico and in vitro cDNA analysis of 21 putative BRCA1 and BRCA2 splice variants and a complex tandem duplication in BRCA2 allowing the identification of activated cryptic splice donor sites in BRCA2 exon 11.
Baert A; Machackova E; Coene I; Cremin C; Turner K; Portigal-Todd C; Asrat MJ; Nuk J; Mindlin A; Young S; MacMillan A; Van Maerken T; Trbusek M; McKinnon W; Wood ME; Foulkes WD; Santamariña M; de la Hoya M; Foretova L; Poppe B; Vral A; Rosseel T; De Leeneer K; Vega A; Claes KBM
Hum Mutat; 2018 Apr; 39(4):515-526. PubMed ID: 29280214
[TBL] [Abstract][Full Text] [Related]
29. Pathogenicity reclassification of two BRCA1/BRCA2 exonic duplications after identification of genomic breakpoints and tandem orientation.
Pinheiro M; Peixoto A; Santos C; Escudeiro C; Bizarro S; Pinto P; Santos R; Pinto C; Guerra J; Silva J; Teixeira MR
Cancer Genet; 2020 Oct; 248-249():18-24. PubMed ID: 32971473
[TBL] [Abstract][Full Text] [Related]
30. Risk factors for lymph node metastasis of ovarian, fallopian tube and primary peritoneal cancer in hereditary breast and ovarian cancer syndrome.
Mitamura T; Sekine M; Arai M; Shibata Y; Kato M; Yokoyama S; Yamashita H; Watari H; Yabe I; Nomura H; Enomoto T; Nakamura S;
Jpn J Clin Oncol; 2020 Dec; 50(12):1380-1385. PubMed ID: 32676635
[TBL] [Abstract][Full Text] [Related]
31. Identifying sequence variants contributing to hereditary breast and ovarian cancer in BRCA1 and BRCA2 negative breast and ovarian cancer patients.
Jarhelle E; Riise Stensland HMF; Hansen GÅM; Skarsfjord S; Jonsrud C; Ingebrigtsen M; Strømsvik N; Van Ghelue M
Sci Rep; 2019 Dec; 9(1):19986. PubMed ID: 31882575
[TBL] [Abstract][Full Text] [Related]
32. Identification of a Splice Variant (c.5074+3A>C) of
Hong J; Kim JH; Ahn SH; Gu H; Chang S; Lee W; Kim DY; Chun S; Min WK
Genes (Basel); 2021 May; 12(6):. PubMed ID: 34073420
[TBL] [Abstract][Full Text] [Related]
33. Incorporation of semi-quantitative analysis of splicing alterations for the clinical interpretation of variants in BRCA1 and BRCA2 genes.
Montalban G; Bonache S; Moles-Fernández A; Gadea N; Tenés A; Torres-Esquius S; Carrasco E; Balmaña J; Diez O; Gutiérrez-Enríquez S
Hum Mutat; 2019 Dec; 40(12):2296-2317. PubMed ID: 31343793
[TBL] [Abstract][Full Text] [Related]
34. Hereditary breast and ovarian cancer in Andalusian families: a genetic population study.
Pajares B; Porta J; Porta JM; Sousa CF; Moreno I; Porta D; Durán G; Vega T; Ortiz I; Muriel C; Alba E; Márquez A
BMC Cancer; 2018 Jun; 18(1):647. PubMed ID: 29884136
[TBL] [Abstract][Full Text] [Related]
35. OLA1 gene sequencing in patients with BRCA1/2 mutation-negative suspected hereditary breast and ovarian cancer.
Takahashi M; Chiba N; Shimodaira H; Yoshino Y; Mori T; Sumii M; Nomizu T; Ishioka C
Breast Cancer; 2017 Mar; 24(2):336-340. PubMed ID: 27271530
[TBL] [Abstract][Full Text] [Related]
36. cDNA analysis demonstrates that the BRCA2 intronic variant IVS4-12del5 is a deleterious mutation.
Zhang L; Bacares R; Boyar S; Hudis C; Nafa K; Offit K
Mutat Res; 2009 Apr; 663(1-2):84-9. PubMed ID: 19070627
[TBL] [Abstract][Full Text] [Related]
37. Mutation screening of TP53, CHEK2 and BRCA genes in patients at high risk for hereditary breast and ovarian cancer (HBOC) in Brazil.
Cipriano NM; de Brito AM; de Oliveira ES; de Faria FC; Lemos S; Rodrigues AN; de Oliveira Lopes D; Dos Santos LL
Breast Cancer; 2019 May; 26(3):397-405. PubMed ID: 30535581
[TBL] [Abstract][Full Text] [Related]
38. Prioritizing Variants in Complete Hereditary Breast and Ovarian Cancer Genes in Patients Lacking Known BRCA Mutations.
Caminsky NG; Mucaki EJ; Perri AM; Lu R; Knoll JH; Rogan PK
Hum Mutat; 2016 Jul; 37(7):640-52. PubMed ID: 26898890
[TBL] [Abstract][Full Text] [Related]
39. Novel de novo BRCA2 mutation in a patient with a family history of breast cancer.
Hansen TV; Bisgaard ML; Jønson L; Albrechtsen A; Filtenborg-Barnkob B; Eiberg H; Ejlertsen B; Nielsen FC
BMC Med Genet; 2008 Jul; 9():58. PubMed ID: 18597679
[TBL] [Abstract][Full Text] [Related]
40. Intronic variants in BRCA1 and BRCA2 that affect RNA splicing can be reliably selected by splice-site prediction programs.
Vreeswijk MP; Kraan JN; van der Klift HM; Vink GR; Cornelisse CJ; Wijnen JT; Bakker E; van Asperen CJ; Devilee P
Hum Mutat; 2009 Jan; 30(1):107-14. PubMed ID: 18693280
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]